Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (B16 RNA-Seq)

ABSTRACT: Defective transcription elongation in a subset of cancers confers immunotherapy resistance (B16 RNA-Seq)

PROVIDER: PRJNA489889 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7807472.fastq.gz	Fastqsanger.gz
	SRR7807473.fastq.gz	Fastqsanger.gz
	SRR7807474.fastq.gz	Fastqsanger.gz
	SRR7807475.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (B16 ChIP-Seq)

Project description:The nature and the role of global transcriptional deregulations in cancers are not fully understood. We report a phenotype in a significant portion of cancers characterized by widespread defects in mRNA transcription elongation (TE). Cancers with TE defects (TEdeff) were characterized by spurious transcription and defective mRNA processing, specifically in a large set of genes characterized by long genomic length, poised promoters and inducible expression. As such, signaling pathways regulated by such genes, such as interferon/JAK/STAT and TNF/NF-κB pathways, were consistently suppressed in TEdeff tumors. Remarkably, TEdeff significantly correlated with the poor response and outcome in immunotherapy, but not chemo- or targeted therapy, -treated renal cell carcinoma and metastatic melanoma patients in 4 different cohorts. Importantly, forced pharmacologic or genetic induction of TEdeff in tumor cells impaired the expression of the interferon/JAK/STAT and TNF/NF-κB pathways, and imposed resistance to the innate and adaptive anti-tumor immune responses and checkpoint inhibitor therapy in vivo. Therefore, defective TE is a novel epigenetic mechanism in the tumor arsenal of immune resistance tools, which warrants its assessment in cancer patients undergoing immunotherapy.

2018-09-08 | GSE119677 | GEO

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (B16 RNA-Seq)

2018-09-08 | GSE119673 | GEO

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (B16 ChIP-Seq)

Project description:Defective transcription elongation in a subset of cancers confers immunotherapy resistance (B16 ChIP-Seq)

| PRJNA489893 | ENA

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (human ChIP-Seq)

2018-09-08 | GSE119676 | GEO

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (BGI12 RNA-Seq)

2018-09-08 | GSE119674 | GEO

Defective transcription elongation in a subset of cancers confers immunotherapy resistance

Project description:Defective transcription elongation in a subset of cancers confers immunotherapy resistance

| PRJNA489885 | ENA

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (human cell lines RNA-Seq)

2018-09-08 | GSE119678 | GEO

Defective transcription elongation in a subset of cancers confers immunotherapy resistance.

Project description:The nature and role of global transcriptional deregulations in cancers are not fully understood. We report that a large proportion of cancers have widespread defects in mRNA transcription elongation (TE). Cancers with TE defects (TEdeff) display spurious transcription and defective mRNA processing of genes characterized by long genomic length, poised promoters and inducible expression. Signaling pathways regulated by such genes, such as pro-inflammatory response pathways, are consistently suppressed in TEdeff tumors. Remarkably, TEdeff correlates with the poor response and outcome in immunotherapy, but not chemo- or targeted therapy, -treated renal cell carcinoma and metastatic melanoma patients. Forced pharmacologic or genetic induction of TEdeff in tumor cells impairs pro-inflammatory response signaling, and imposes resistance to the innate and adaptive anti-tumor immune responses and checkpoint inhibitor therapy in vivo. Therefore, defective TE is a previously unknown mechanism of tumor immune resistance, and should be assessed in cancer patients undergoing immunotherapy.

| S-EPMC6199328 | biostudies-literature

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (human ChIP-Seq)

Project description:Defective transcription elongation in a subset of cancers confers immunotherapy resistance (human ChIP-Seq)

| PRJNA489890 | ENA

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (BGI12 RNA-Seq)

Project description:Defective transcription elongation in a subset of cancers confers immunotherapy resistance (BGI12 RNA-Seq)

| PRJNA489891 | ENA